CCR1

Across TCGA pan-cancer cohorts, CCR1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCR1 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CCR1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CCR1 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where CCR1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.750	0.934	.006	20	view →
LSCC	DFS	Median	III,IV	0.988	0.625	.029	8	view →
HNSC	DFS	Median	II,III,IV	0.944	0.686	.018	4	view →
LUAD	DFS	Tertile	II,III,IV	0.667	0.380	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CCR1–PDAC (OS)

Open the PDAC breakdown →